English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Diabetic complications are detrimental problem and the most prevalent cause of morbidity and mortality among the people with Type 2 diabetes mellitus (Morrish et al., 2001). Type 2 diabetes mellitus is a metabolic disease characterized by hyperglycemia resulting from declining beta cell function and insulin resistance (American Diabetes Association, 2011). India has the highest population suffering from diabetes across the world (Kaveeshwar and Cornwall J, 2014). The prevalence of diabetes was 415 million in 2015 and expected to rise to 642 million by 2040 with a maximum increase in India (Whiting et al., 2011). Epidemiological studies demonstrated, 85% of diabetics in the world are suffering from diabetic dyslipidemia. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride (TG) levels, low high-density lipoprotein cholesterol (HDL-C) levels and a high proportion of small dense low-density lipoprotein cholesterol (Mooradian, 2009). Despite numerous antidiabetic drugs are identified, the prominent combination therapy for management of diabetes is still unavailable. The combination therapy based on the rationale with the multitargeted approach has a vital role in the management of diabetes and related complications. Therefore, there is need to identify the combination that improves glycemic and lipid control and reduce the risk of life threatening complications.

A protective effect of DPP4 inhibitor and dual PPAR agonist combination on diabetes and its complications